Last reviewed · How we verify

ICE

MedImmune LLC · FDA-approved active Small molecule

ICE is an intracellular caspase inhibitor that blocks apoptosis by inhibiting caspase enzymes responsible for programmed cell death.

At a glance

Generic nameICE
SponsorMedImmune LLC
Drug classCaspase inhibitor
TargetCaspase-1 (ICE)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

ICE (Interleukin-1β Converting Enzyme, also known as caspase-1) inhibitors work by blocking the enzymatic activity of caspases, which are proteases that execute apoptotic cell death pathways. By preventing caspase activation, these inhibitors can reduce unwanted cell death in tissues affected by inflammatory or degenerative conditions. This mechanism has been explored primarily in inflammatory and neurological disorders.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: